Traore I, Eberst G, Claudé F, Laurent L, Meurisse A, Paget-Bailly S, Roux-Claudé P, Jacoulet P, Barnig C, Martarello R, Poirson B, Bouiller K, Chirouze C, Behr J, Grillet F, Ritter O, Pili-Floury S, Winiszewski H, Samain E, Capellier G, Westeel V

Nat Sci Sleep. 2022 12 22;14:2213-2225

Result of one-year, prospective follow-up of intensive care unit survivors after SARS-CoV-2 pneumonia.

Eberst G, Claudé F, Laurent L, Meurisse A, Roux-Claudé P, Barnig C, Vernerey D, Paget-Bailly S, Bouiller K, Chirouze C, Behr J, Grillet F, Ritter O, Karaer S, Pili-Floury S, Winiszewski H, Samain E, Decavel P, Capellier G, Westeel V

Ann Intensive Care. 2022 Mar 9;12(1):23

HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study.

Baumann A, Henriques J, Selmani Z, Meurisse A, Lepiller Q, Vernerey D, Valmary-Degano S, Paget-Bailly S, Riethmuller D, Ramanah R, Mougin C, Prétet JL

Cancers (Basel). 2021 Aug 18;13(16):

Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.

Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V

Cochrane Database Syst Rev. 2021 Apr 30;4:CD013257

An international tool to measure perceived stressors in intensive care units: the PS-ICU scale.

Laurent A, Fournier A, Lheureux F, Martin Delgado MC, Bocci MG, Prestifilippo A, Aslanian P, Henriques J, Paget-Bailly S, Constantin JM, Besch G, Quenot JP, Anota A, Bouhemad B, Capellier G

Ann Intensive Care. 2021 Apr 10;11(1):57

Feasibility of a prehabilitation programme dedicated to older patients with cancer before complex medical-surgical procedures: the PROADAPT pilot study protocol.

Roche M, Ravot C, Malapert A, Paget-Bailly S, Garandeau C, Pitiot V, Tomatis M, Riche B, Galamand B, Granger M, Barbavara C, Bourgeois C, Genest E, Stefani L, Haïne M, Castel-Kremer E, Morel-Soldner I, Collange V, Le Saux O, Dayde D, Falandry C,

BMJ Open. 2021 Apr 2;11(4):e042960

Quality of patient-reported outcome reporting according to the CONSORT statement in randomized controlled trials with glioblastoma patients.

Garnier L, Charton E, Falcoz A, Paget-Bailly S, Vernerey D, Jary M, Ducray F, Curtit E

Neurooncol Pract. 2021 Apr;8(2):148-159

Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice.

Mouillet G, Falcoz A, Fritzsch J, Almotlak H, Jacoulet P, Pivot X, Villanueva C, Mansi L, Kim S, Curtit E, Meneveau N, Adotevi O, Jary M, Eberst G, Vienot A, Calcagno F, Pozet A, Djoumakh O, Borg C, Westeel V, Anota A, Paget-Bailly S

Qual Life Res. 2021 Jan 2;:

Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.

Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V

Cochrane Database Syst Rev. 2020 Dec 14;12:CD013257

Impact of routine assessment of health-related quality of life coupled with therapeutic information on compliance with endocrine therapy in patients with non-metastatic breast cancer: protocol for a randomized controlled trial.

Mamguem Kamga A, Di Martino C, Anota A, Paget-Bailly S, Coutant C, Arveux P, Desmoulins I, Dabakuyo-Yonli TS

Trials. 2020 Jun 16;21(1):527

[Adjuvant hormonal therapy for early breast cancer: Assessment of patients' satisfaction].

Vardanega J, Henriques J, Pourcelot C, Dirand C, Nallet G, Brédart A, Anota A, Chaigneau L, Curtit E, Limat S, Paget-Bailly S, Nerich V

Bull Cancer. 2019 Oct 12;:

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.

Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, Paget-Bailly S, Henriques J, Grouin JM,

Lancet. 2019 Jun 6;:

Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol.

Mouillet G, Fritzsch J, Paget-Bailly S, Pozet A, Es-Saad I, Meurisse A, Vernerey D, Mouyabi K, Berthod D, Bonnetain F, Anota A, Thiery-Vuillemin A

Health Qual Life Outcomes. 2019 Feb 4;17(1):25

Impact of BRCA status on outcomes and survival in high-risk early breast cancers.

Klajer E, Paget-Bailly S, Meynard G, Meurisse A, Bazan F, Chaigneau L, Dobi E, Meneveau N, Montcuquet P, Villanueva C, Thiery-Vuillemin A, Kalbacher E, Populaire C, Collonge-Rame MA, Gligorov J, Curtit E, Pivot X, Mansi L

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii68

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

Jacquinot Q, Paget-Bailly S, Fumoleau P, Romieu G, Pierga JY, Espié M, Lortholary A, Nabholtz JM, Mercier CF, Pauporté I, Henriques J, Pivot X

Breast. 2018 Jun 15;41:1-7

Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence.

Pourcelot C, Orillard E, Nallet G, Dirand C, Billion-Rey F, Barbier G, Chouk S, Limat S, Montcuquet P, Henriques J, Paget-Bailly S, Anota A, Chaigneau L, Nerich V

Breast Cancer Res. Treat.. 2018 May;169(1):153-162

3 Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

André T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egreteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J,

J. Clin. Oncol.. 2018 Apr 5;:JCO2017760355

Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study.

Turpin A, Paget-Bailly S, Ploquin A, Hollebecque A, Peugniez C, El-Hajbi F, Bonnetain F, Hebbar M

Clin Colorectal Cancer. 2018 Mar;17(1):e99-e107

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.

Curtit E, Pivot X, Henriques J, Paget-Bailly S, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Kerbrat P, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Thomas G, Deleuze JF, Pauporté I, Romieu G, Cox DG

Breast Cancer Res.. 2017 Aug;19(1):98

Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.

Pivot X, Fumoleau P, Pierga JY, Delaloge S, Bonnefoi H, Bachelot T, Jouannaud C, Bourgeois H, Rios M, Soulié P, Jacquin JP, Lavau-Denes S, Kerbrat P, Cox D, Faure-Mercier C, Pauporte I, Gligorov J, Curtit E, Henriques J, Paget-Bailly S, Romieu G

Eur. J. Cancer. 2017 Jun;81:151-160

Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma.

Kim S, Paget-Bailly S, Messager M, Nguyen T, Mathieu P, Lamfichekh N, Fein F, Fratté S, Cléau D, Lakkis Z, Jary M, Sakek N, Jacquin M, Foubert A, Bonnetain F, Mariette C, Fiteni F, Borg C

Eur J Surg Oncol. 2017 Jan;43(1):218-225

[Assessment of the quality of life with regard to health following a cancer diagnosis].

Es-Saad I, Paget-Bailly S, Fritzsch J, Mouillet G, Bonnetain F

Rev Infirm. 2017 Jan;66(227):36-37

Development and validation of the FRAGIRE tool for assessment an older person's risk for frailty.

Vernerey D, Anota A, Vandel P, Paget-Bailly S, Dion M, Bailly V, Bonin M, Pozet A, Foubert A, Benetkiewicz M, Mankoundia P, Bonnetain F

BMC Geriatr. 2016 Nov;16(1):187

Docetaxel, Cisplatin, and 5-Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma.

Fiteni F, Paget-Bailly S, Messager M, N'Guyen T, Lakkis Z, Mathieu P, Lamfichekh N, Picard A, Benzidane B, Cléau D, Bonnetain F, Borg C, Mariette C, Kim S

Cancer Med. 2016 Nov;5(11):3085-3093

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP).

Vernerey D, Huguet F, Vienot A, Goldstein D, Paget-Bailly S, Van Laethem JL, Glimelius B, Artru P, Moore MJ, André T, Mineur L, Chibaudel B, Benetkiewicz M, Louvet C, Hammel P, Bonnetain F

Br. J. Cancer. 2016 Jul;115(3):281-9

In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?

Pivot X, Mansi L, Chaigneau L, Montcuquet P, Thiery-Vuillemin A, Bazan F, Dobi E, Sautiere JL, Rigenbach F, Algros MP, Butler S, Jamshidian F, Febbo P, Svedman C, Paget-Bailly S, Bonnetain F, Villanueva C

Oncologist. 2015 Mar 20. pii: theoncologist.2014-0198.

Occupational Exposure to Diesel Motor Exhaust and Lung Cancer: A Dose-Response Relationship Hidden by Asbestos Exposure Adjustment? The ICARE Study.

Matrat M, Guida F, Cenee S, Fevotte J, Carton M, Cyr D, Menvielle G, Paget-Bailly S, Radoi L, Schmaus A, Bara S, Velten M, Luce D, Stucker I, The Icare Study Group

J Cancer Epidemiol. 2015;2015:879302

The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas.

Kim S, Fiteni F, Paget-Bailly S, Ghiringhelli F, Lakkis Z, Jary M, Fein F, Bonnetain F, Mariette C, Borg C

J Hematol Oncol. 2015 May 15;8(1):52

Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?

Anota A, Hamidou Z, Paget-Bailly S, Chibaudel B, Bascoul-Mollevi C, Auquier P, Westeel V, Fiteni F, Borg C, Bonnetain F

Qual Life Res. 2015 Jan;24(1):5-18

Occupation and head and neck cancer in women-Results of the ICARE study.

Carton M, Guida F, Paget-Bailly S, Cyr D, Radoi L, Sanchez M, Schmaus A, Cénée S, Papadopoulos A, Menvielle G, Févotte J, Pilorget C, Molinié F, Bara S, Stücke I, Luce D

Am. J. Ind. Med.. 2014 Dec;57(12):1386-97

Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.

Jary M, Ghiringhelli F, Jacquin M, Fein F, Nguyen T, Cleau D, Nerich V, El Gani M, Mathieu P, Valmary-Degano S, Arnould L, Lassabe C, Lamfichekh N, Fratte S, Paget-Bailly S, Bonnetain F, Borg C, Kim S

Cancer Chemother Pharmacol. 2014 Jul;74(1):141-50